Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy

BACKGROUND AND PURPOSE

(1) To establish a method to evaluate dosimetry at the time of primary prostate permanent implant (pPPI) using MRI of the shrunken prostate at the time of failure (tf). (2) To compare cold spot mapping with sextant-biopsy mapping at tf.

MATERIAL AND METHODS

Twenty-four patients were referred for biopsy-proven local failure (LF) after pPPI. Multiparametric MRI and combined-sextant biopsy with a central review of the pathology at tf were systematically performed. A model of the shrinking pattern was defined as a Volumetric Change Factor (VCF) as a function of time from time of pPPI (t0). An isotropic expansion to both prostate volume (PV) and seed position (SP) coordinates determined at tf was performed using a validated algorithm using the VCF.

RESULTS

pPPI CT-based evaluation (at 4weeks) vs. MR-based evaluation: Mean D90% was 145.23±19.16Gy [100.0-167.5] vs. 85.28±27.36Gy [39-139] (p=0.001), respectively. Mean V100% was 91.6±7.9% [70-100%] vs. 73.1±13.8% [55-98%] (p=0.0006), respectively. Seventy-seven per cent of the pathologically positive sextants were classified as cold.

CONCLUSIONS

Patients with biopsy-proven LF had poorer implantation quality when evaluated by MRI several years after implantation. There is a strong relationship between microscopic involvement at tf and cold spots.

Inverse planning optimization for hybrid prostate permanent-seed implant brachytherapy plans using two source strengths

The purpose is to demonstrate the ability to generate clinically acceptable prostate permanent seed implant plans using two seed types which are identical except for their activity. The IPSA inverse planning algorithms were modified to include multiple dose matrices for the calculation of dose from different sources, and a selection algorithm was implemented to allow for the swapping of source type at any given source position. Five previously treated patients with a range of prostate volumes from 20-48 cm3 were re-optimized under two hybrid scenarios: (1) using 0.32 and 0.51 mGy m2 / h 125I, and (2) using 0.64 and 0.76 mGy m2 / h 125I. Isodose lines were generated and dosimetric indices , V150Prostate, D90Prostate, V150Urethra, V125Urethra, V120Urethra,V100Urethra, and D10Urethra were calculated. The algorithm allows for the generation of single-isotope, multi-activity hybrid brachytherapy plans. By dealing with only one radionuclide, but of different activity, the biology is unchanged from a standard plan. All V100Prostate were within 2.3 percentage points for every plan and always above the clinically desirable 95%. All V150Urethra were identically zero, and V120Urethra is always below the clinically acceptable value of 1.0 cm3. Clinical optimization times for the hybrid plans are still under one minute, for most cases. It is possible to generate clinically advantageous brachytherapy plans (i.e. obtain the same quality dose distribution as a standard single-activity plan) while incorporating leftover seeds from a previous patient treatment. This method will allow a clinic to continue to provide excellent patient care, but at a reduced cost. Multi-activity hybrid plans were equal in quality (as measured by the standard dosimetric indices) to plans with seeds of a single activity. Despite the expanded search space, optimization times for these studies were still under two minutes on a modern day laptop and can be reduced to below one minute in a clinical setting. With the typical cost of a set of PPI seeds on the order of thousands of dollars, it is possible to reduce the cost of brachytherapy treatments by allowing for easier use of seeds left over from a previous patient or unused due to a cancelled treatment.

Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience

PURPOSE

To retrospectively determine if pretreatment endorectal magnetic resonance (MR) imaging findings are predictive of outcome in patients who undergo external-beam radiation therapy for prostate cancer.

MATERIALS AND METHODS

Committee on Human Research approval, with waiver of the requirement for informed consent, was obtained for this HIPAA-compliant study. Eighty men with biopsy-proved prostate cancer (mean age, 59 years; range, 47-75 years) who underwent endorectal MR imaging of the prostate prior to external-beam radiation therapy were retrospectively identified; details of baseline tumor characteristics, treatment, and outcome were recorded. Two experienced readers independently reviewed all MR imaging studies and recorded tumor T stage and the radial diameter of extracapsular extension (if present). Univariate and multivariate stepwise Cox regression analyses were used to investigate the relationship between baseline imaging and clinical predictive variables and the end point of metastatic failure.

RESULTS

At MR imaging, readers 1 and 2, respectively, considered 50 and 60 patients to have T1 or T2 disease (ie, organ-confined disease) and 30 and 20 patients to have T3 disease. After a mean follow-up of 43 months, four patients developed metastases. Univariate Cox analysis revealed that baseline serum prostate-specific antigen level, presence of extracapsular extension at MR imaging (according to either reader), and degree of extracapsular extension (according to either reader) were all significantly (P < .05) related to the development of metastases. Multivariate Cox analysis revealed that the sole independent predictive variable was mean diameter of extracapsular extension (relative hazard ratio, 2.06; 95% confidence interval: 1.22, 3.48; P = .007). In particular, three of five patients with extracapsular extension of more than 5 mm at pretreatment MR imaging developed metastases 24, 43, and 63 months after therapy.

CONCLUSION

The presence and degree of extracapsular extension at MR imaging prior to external-beam radiation therapy are important predictors of posttreatment metastatic recurrence.

The use of megavoltage cone-beam CT to complement CT for target definition in pelvic radiotherapy in the presence of hip replacement

In Europe and the USA combined, over half a million people had a hip joint replaced in 2005, contributing to the increasing number of radiotherapy patients with metallic hip prostheses. The treatment plan for external beam radiation therapy is based on the delineation of the anatomy in the planning CT scan. When implanted objects of high atomic number (Z) material are present, however, severe image artefacts are generated in conventional CT, strongly hindering the ability to delineate some organs. This is particularly the case for the planning of prostate patients with hip prostheses. This short communication presents the use of a new imaging modality, megavoltage cone-beam CT, to complement the regular CT for target definition of prostate cancer treatment of patients with hip replacements.

Class solution for inversely planned permanent prostate implants to mimic an experienced dosimetrist

The purpose of this paper is to present a method for the selection of inverse planning parameters and to establish a set of inverse planning parameters (class solution) for the inverse planning included in a commercial permanent prostate implant treatment planning system. The manual planning of more than 750 patients since 1996 led to the establishment of general treatment planning rules. A class solution is tuned to fulfill the treatment planning rules and generate equivalent implants. For ten patients, the inverse planning is compared with manual planning performed by our experienced physicist. The prostate volumes ranged from 17 to 51 cc and are implanted with low activity 1-125 seeds. Dosimetric indices are calculated for comparison. The inverse planning needed about 15 s for each optimization (400 000 iterations on a 2.5 GHz PC). In comparison, the physicist needed about 20 min to perform each manual plan. A class solution is found that consistently produces dosimetric indices equivalent or better than the manual planning. Moreover, even with strict seed placement rules, the inverse planning can produce adequate prostate dose coverage and organ at risk protection. The inverse planning avoids implant with seeds outside of the prostate and too close to the urethra. It also avoids needles with only one seed and needles with three consecutive seeds. This reduces the risk of complication due to seed misplacement and edema. The inverse planning also uses a smaller number of needles, reducing the cause of trauma. The quality of the treatment plans is independent of the gland size and shape. A class solution is established that consistently and rapidly produces equivalent dosimetric indices as manual planning while respecting severe seed placement rules. The class solution can be used as a starting point for every patient, dramatically reducing the time needed to plan individual patient treatments. The class solution works with inverse preplanning, intraoperative inverse preplanning, and intraoperative real-time planning. This technology is not intended to replace the physicist but to accelerate the planning process, making intraoperative treatment planning more effective.

Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level

PURPOSE

To evaluate the metabolic response by comparing the time to resolution of spectroscopic abnormalities (TRSA) and the time to prostate-specific antigen level in low-risk prostate cancer patients after treatment with three-dimensional conformal external beam radiotherapy (3D-CRT) compared with permanent prostate implantation (PPI). Recent studies have suggested that the treatment of low-risk prostate cancer yields similar results for patients treated with 3D-CRT or PPI.

METHODS AND MATERIALS

A total of 50 patients, 25 in each group, who had been treated with 3D-CRT or PPI, had undergone endorectal magnetic resonance spectroscopy imaging before and/or at varying times after therapy. The 3D-CRT patients had received radiation doses of > or =72 Gy compared with 144 Gy for the PPI patients. The spectra from all usable voxels were examined for detectable levels of metabolic signal, and the percentages of atrophic and cancerous voxels were tabulated.

RESULTS

The median time to resolution of the spectroscopic abnormalities was 32.2 and 24.8 months and the time to the nadir prostate-specific antigen level was 52.4 and 38.0 months for the 3D-CRT and PPI patients, respectively. Of the 3D-CRT patients, 92% achieved negative endorectal magnetic resonance spectroscopy imaging findings, with 40% having complete metabolic atrophy. All 25 PPI patients had negative endorectal magnetic resonance spectroscopy imaging findings, with 60% achieving complete metabolic atrophy.

CONCLUSION

The results of this study suggest that metabolic and biochemical responses of the prostate are more pronounced after PPI. Our results have not proved PPI is more effective at curing prostate cancer, but they have demonstrated that it may be more effective at destroying prostate metabolism.

Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer

PURPOSE

To characterize the metabolic response in the prostate, the time to resolution of disease, and the correlation between magnetic resonance imaging (MRI) with spectroscopy (MRSI) results, biopsy findings, and serum prostate-specific antigen (PSA) level after external beam radiotherapy.

METHODS AND MATERIALS

A total of 55 patients underwent MRSI before and/or at varying times after external beam radiotherapy. The percentage of the cancerous, healthy, and atrophic voxels was calculated, and the time to resolution of disease was determined and compared with the PSA nadir.

RESULTS

Of the 55 patients, 70% had negative MRSI and 30% had positive MRSI findings. A strong correlation was found between negative MRSI and negative biopsy findings (n = 11) and between positive MRSI and positive biopsy findings (n = 7). A weak correlation was observed between the PSA level and the MRSI and biopsy findings. The mean time to disease resolution was 40.3 months and the mean time to PSA nadir was 50 months. With time, an increase in atrophy and a decline in cancerous metabolism was found.

CONCLUSION

When used in conjunction with PSA measurement and biopsy, the results of this study suggest that MRSI contributes to a greater level of confidence in determining the outcome and may be a useful adjunct for assessing local control before PSA failure when striving to distinguish the benign "blip" from local recurrence.

Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience

PURPOSE

To evaluate endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging for the depiction of locally recurrent prostate cancer after external beam radiation therapy.

MATERIALS AND METHODS

Endorectal MR imaging and MR spectroscopic imaging were performed in 21 patients with biochemical failure after external beam radiation therapy for prostate cancer. Two readers independently and retrospectively reviewed MR images and rated the likelihood of recurrent tumor on a five-point scale. Spectroscopic voxels were considered suspicious for malignancy if the choline level was elevated and citrate was absent. Receiver operating characteristic curve analysis was used to assess cancer detection in each side of the prostate with endorectal MR imaging and spectroscopic imaging at different thresholds based on the scores assigned by the two readers and on the number of suspicious voxels in each hemiprostate, respectively. The presence or absence of cancer at subsequent transrectal biopsy was used as the standard of reference.

RESULTS

Biopsy demonstrated locally recurrent prostate cancer in nine hemiprostates in six patients. The area under the receiver operating characteristic curve for the detection of locally recurrent cancer with MR imaging was 0.49 and 0.51 for readers 1 and 2, respectively. By using the number of suspicious voxels to define different diagnostic thresholds, the area under the receiver operating characteristic curve for MR spectroscopic imaging was significantly (P < .005) higher, at 0.81. In particular, the presence of three or more suspicious voxels in a hemiprostate showed a sensitivity and specificity of 89% and 82%, respectively, for the diagnosis of local recurrence. Seven hemiprostates demonstrated complete metabolic atrophy at spectroscopic imaging and only postirradiation atrophy at biopsy.

CONCLUSION

Preliminary data suggest that MR spectroscopic imaging, but not endorectal MR imaging, may be of value for the depiction of locally recurrent prostate cancer after radiation therapy.

The effect of the radial function on I-125 seeds used for permanent prostate implantation

The purpose of this study was to evaluate the integrity of eight commercially-available low-activity Iodine-125 (125I) seeds for their radial function g(r) and its effect on the dose delivered to the adjacent critical structures when used in permanent prostate implants (PPI). Ten previously treated patients were retrospectively used in this comparison. The Amersham Health Oncura seed was used to peripherally design an isodose distribution with urethral and anterior rectal wall sparing. Plan criteria included minimum coverage of 144 Gy to the planning target volume (PTV), < or = 70% dose to 150% of the PTV volume (V150-PTV), and the quantity of needles < or = 70% of the size of the PTV, in cc. Upon completion of the Oncura plan, the seed type was changed and the activity was adjusted until the V100-PTV for each of the other 7 seed types matched the V100-PTV defined by the Oncura seed. Computed tomography (CT)-based postimplant dosimetry was used to determine the dose to 40% (D40) of the bulb of the penis (in Gy). Dose-volume histograms (DVH) were used to evaluate the differences to V100 (in %) and D40 (in Gy) of the anterior rectal wall and bulb of the penis, and V100 (in %) of the urethra. The data was tabulated. Radioactive 125I sources included in this study were 125I Source 2301 (Best); I-Plant (MedTech), IoGold (Mentor), Oncura (Amersham Health), ProstaSeed (UroCor), SelectSeed (Nucletron), SourceTech (Bard), and Symmetra (UroMed). The sizes of the PTV for the 10 patients ranged from 18.82 cc to 48.99 cc. The Oncura seed was used as the reference seed and all other seed types were normalized to it for data comparison. It was determined that the dose rate constant (Delta) and anisotropy factor (phi) contribute to the activity needed to achieve comparable V100-PTV doses, but a strong dependence on the radial function g(r) was found to effect the doses to the critical structures studied. Values of g(r) at 4 cm were calculated and the IoGold and SourceTech seeds were determined to have the highest g(r) values, with ProstaSeed and SelectSeed having the lowest values. 125I Source 2301 and IoGold required less activity per seed to achieve the same dose to the V100-PTV due to the higher dose rate and anisotrophy constants (Delta.phi). The seed types with silver were less penetrating and resulted in the production of characteristic x-rays that modified the energy spectrum and influenced the radial function. The seeds requiring the lowest activity showed the highest dose to the anterior rectal wall, a posterior adjacent structure; the urethra, an interior structure; and the bulb, an inferior structure. This study was designed to investigate the integrity of eight different commercially-available seed types, and their dependence on the g(r) in seed choice. It was determined that the dose rate constant and anisotropy factor determine the activity needed for implantation but a strong dependence on the radial function was found to effect the doses to the adjacent structures.

Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging

PURPOSE

To characterize the time to metabolic atrophy (TMA) after permanent prostate implantation (PPI) using combined MRI and magnetic resonance spectroscopic imaging (MRSI) compared with the time to prostate-specific antigen (PSA) nadir.

METHODS AND MATERIALS

This study was based on a posttreatment analysis comparing the MRI/MRSI findings with the PSA levels of 65 patients treated with PPI alone or combined with external beam radiotherapy and/or HT. The fraction of interpretable voxels demonstrating metabolic atrophy was used to compare the TMA with the time to PSA nadir.

RESULTS

The fraction of patients with metabolic atrophy in >95% of usable voxels after PPI increased from approximately 46% to 100% at 6 and 48 months, respectively. The mean time for PSA nadir vs. TMA was 42.5 vs. 28.9 months (PPI), 32.8 vs. 25.6 months (external beam radiotherapy + PPI), and 25.3 vs. 28.0 months (external beam radiotherapy + hormonal therapy + PPI).

CONCLUSION

Magnetic resonance spectroscopic imaging may provide an early tool for evaluating the treatment response for patients treated with PPI. If supported by longer follow-up, TMA may be a useful adjunct to PSA measurement for assessing local control after PPI and could be useful in evaluating the complex relationships between the quality of the implant and the time to indication of successful therapy.

(Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device

PURPOSE

Radiopaque gold markers can be implanted in the prostate to visualize its position on portal images during radiation therapy. This procedure assumes that the markers do not move within the prostate. In this work we test this assumptiom.

METHODS AND MATERIALS

Three markers were implanted transrectally in the prostate of patients undergoing external radiation therapy. An orthogonal pair of portal images was acquired periodically throughout the course of radiation therapy with an a-Si electronic portal imaging device (EPID). The marker coordinates were determined, and the distances between the implanted markers were recorded. The distance time trend is used to evaluate the magnitude of marker migration.

RESULTS

The average standard deviation (SD) of the distances between markers was 1.3 mm (range 0.44 to 3.04 mm). Three of the 11 patients show a SD larger than 2 mm. For these patients, all three distances show a simultaneous reduction with time, compatible with a shrinking of the prostate. All had been treated with neoadjuvant hormone therapy. For 1 of the 3 patients, this reduction in volume was confirmed with a repeat computed tomographic scan.

CONCLUSION

None of the 33 markers studied migrated significantly. The implantation of three radiopaque gold markers enables accurate and precise on-line verification of the prostate position during external beam radiation therapy. The use of three markers provides a tool to monitor prostate position and volume changes that can occur over time due to hormone or radiation therapy.

The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets

PURPOSE

To examine the influence of energy and number of beams on nontarget dose when using intensity-modulated radiation therapy (IMRT) to treat deep-seated targets.

METHODS AND MATERIALS

Ten patients with prostate cancer (36-226 cc) treated locally to 75.6 Gy were studied. IMRT plans were created for 6-, 10-, and 18-MV photons using 4, 6, 9, and 11 coplanar nonopposed fields. Plans, normalized to cover 95% of the target volume, were analyzed using: (a) conformity index (CI) at 105%, 100%, 95%, 90%, 80%, 70%, 50% of prescribed dose; (b) prescription isodose line (PI); (c) minimum dose to target (Tar(min)); (d) maximum dose to tissue (Tis(max)); (e) dose to rectum/bladder/penis bulb; (f) integral nontarget dose (ID). Because CI evaluates dose independent of location, tissue also was divided into "near region" (NR: 1-cm-thick shell surrounding target) and "far region" (FR: tissue minus NR) volumes that were evaluated at the same levels as CI.

RESULTS

The target and sensitive structure metrics were the same for all plans. However, although there was little difference in NR volume exposed to dose, regardless of energy or number of fields, there was a significant increase in FR volume exposed to dose, at all levels, for low energy/few field plans compared to high energy/many fields (e.g., > 50 cc >or= 65 Gy). This effect disappeared with >or= 9 fields regardless of energy.

CONCLUSION

With IMRT, the use of 6 MV photons with less than 9 fields may result in an increase in dose in regions distant from the target volume (e.g., near the skin surface), even though the CI and sensitive structure metrics may indicate good conformance of high dose to the target volume itself. The clinical significance of this increased dose distant from the target, in terms of complications, remains to be determined.

Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy

PURPOSE

To investigate the technical feasibility of using forward or inversely planned segmental multileaf collimator (SMLC) intensity-modulated radiotherapy and sequential tomotherapy (ST) to escalate to a dose of 90 Gy to multiple dominant intraprostatic lesions within the prostate gland while delivering a dose of 75.6 Gy to the remaining prostate.

METHODS AND MATERIALS

A selected case with one dominant intraprostatic lesion located at the left base and a second dominant intraprostatic lesion at the right apex of the prostate was planned using three different intensity modulation techniques. Two plans were generated with inverse treatment planning, using either SMLC or ST with a special multivane collimator. The third plan also employed SMLC but was generated using forward planning. All three plans were compared based on dose-volume histograms, isodose distributions, and doses to sensitive normal structures.

RESULTS

All three plans meet and exceed the desired dose constraints, limiting doses to the rectum and bladder to an estimated RTOG Grade 2 complication rate of <10%. The ST plan achieved the best dose conformality, whereas the inverse SMLC plan gave the lowest dose to the rectal wall, and the forward SMLC plan obtained the best dose homogeneity inside the targets.

CONCLUSIONS

Using any of the three intensity-modulated techniques, it is technically feasible to concurrently treat multiple selected high-risk regions within the prostate to 90 Gy and the remaining prostate to 75.6 Gy, while keeping the doses to the rectum and the bladder significantly lower than those associated with a Grade 2 complication rate of 10%.

Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer

OBJECTIVES

To evaluate the effect of the dose to the bulb of the penis on postradiation potency.

METHODS

Twenty-one patients reporting potency before three-dimensional conformal radiotherapy had the dose delivered to the bulb of the penis evaluated. This was then compared with the patient assessments of post-treatment sexual function to determine whether a dose-volume relationship exists.

RESULTS

Among the patients analyzed to date, a strong dose-volume relationship and the likelihood of remaining potent after treatment seems to exist. Patients receiving a dose of less than 40 Gy to 70% of the bulb of the penis appear to have a much greater likelihood of maintaining potency. Patients receiving 70 Gy or more to 70% of the bulb of the penis appear to be at very high risk of experiencing radiation-induced impotence (P = 0.03).

CONCLUSIONS

More studies are needed to confirm these observations. If confirmed, these data suggest that by using three-dimensional-based treatment planning and carefully designed treatment fields, the potency of men treated with radiotherapy might be substantially improved.

Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer

OBJECTIVES

To report the toxicity profile of patients treated with three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) receiving doses of 82 Gy or more to portions of their prostate.

METHODS

Forty-four patients treated with radiation therapy for prostate cancer between June 1992 and August 1998 at the University of California, San Francisco received a maximal dose within the target volume (Dmax) of 82 Gy or more. Eighteen patients were boosted selectively to a limited portion of their prostate using IMRT, whereas 26 patients were treated with 3D-CRT and had unselected "hot spots" within their prostate. The Radiation Therapy Oncology Group (RTOG) acute and late toxicity scales were used to score gastrointestinal (GI) and genitourinary (GU) morbidity.

RESULTS

Median follow-up and Dmax were 23.1 months (range 10.0 to 84.7) and 84.5 Gy (range 82.0 to 96.7), respectively. Of the patients, 59.1% and 34.1% developed some level of acute GU and GI toxicity, respectively. One patient experienced grade 3 acute GI toxicity. No other grade 3 or greater acute toxicity was observed. The 2-year actuarial rates for freedom from late GI and GU morbidity were 77.1% (95% confidence interval [CI] 60.4% to 87.5%) and 79.5% (95% CI 62.7% to 89.3%), respectively. Although no grade 3 or greater late GU morbidity has been observed to date, 3 patients experienced grade 3 late GI morbidity. However, these cases involved rectal bleeding and were effectively managed with laser coagulation/fulguration.

CONCLUSIONS

Doses of 82 Gy or more to a portion of the prostate gland can be tolerated with acceptable morbidity. This observation supports the continued investigation of IMRT as a means for improving disease control in prostate cancer.

Prostate volume change after radioactive seed implantation: possible benefit of improved dose volume histogram with perioperative steroid

PURPOSE

To evaluate the changes in prostate volume associated with radioactive seed implantation and identify factors that influence prostate swelling.

METHODS AND MATERIALS

Between June 1997 and August 1999, 161 patients implanted for prostate carcinoma at the University of California, San Francisco, had prostate volume measurements taken at 4 time points (preplan, preimplant, postimplant, postimplant dosimetry). Patient records were reviewed for treatment with perioperative steroids, hormone therapy (nHT), and external beam radiotherapy (EBRT). One and 2-way analysis of variance (ANOVA) methods were used to test differences in mean effects among patient subsets.

RESULTS

A mean 20% volume increase was noted immediately postimplant overall (p < 0.0001), and even with EBRT and/or HT. Steroids were associated with a mean volume decrease of 19.9%, by 3-4 weeks post-procedure (p < 0.0001). Without steroids, only a 3.8% mean change was seen (p = ns). Steroid use resulted in a significant increase in mean dose-volume histogram (DVH) (p = 0.001); however, this benefit was only observed among patients who did not receive steroid. A consistently high DVH occurred with steroid use.

CONCLUSION

A significant decrease in prostate volume and improved DVH are associated with steroid use. The diminished benefit of steroid use and higher mean DVH achieved in later years suggests the existence of a significant "learning curve" for brachytherapy procedures.

Minimal toxicity with 3-FAT radiotherapy of prostate cancer

Beam radiation with three-dimensional conformal planning appears to decrease morbidity of prostate cancer therapy. The 3-field, arc technique (3-FAT) technique was designed by computer modeling to improve radiation dose to the target and minimize dispersion to nearby organs. Toxicity was studied in patients with prostate cancer. We performed a retrospective study of 168 consecutive men with prostate cancer after 3-FAT radiotherapy with a median follow-up of 24 months. All patients, treated from 1996 through 1999 at the University of Colorado had a pathological diagnosis of cancer before irradiation. Therapy was designed with a urethrogram and planning computed tomography scan. The 3-FAT was employed using noncoplanar, rotational beams, and nonuniform blocking of portals. Patients were treated to a minimal tumor dose of 74 Gy in 37 fractions. Adverse effects were investigated. Definitive radiotherapy was given to 80% of the group, and 58% received total androgen blockade. 3-FAT produced favorable dose distributions for the rectum, bladder, femoral heads, and base of the penis. Patients routinely report minimal dysuria and frequency during treatment. There were minimal urinary complaints after irradiation and no proctitis, diarrhea, incontinence, or change in potency as a result of radiotherapy. The 3-FAT represents a technical improvement in the treatment of prostate cancer by minimizing radiation delivered to adjacent critical structures. There were minimal side effects to the rectum, bladder, and penis base despite high doses to the prostate and seminal vesicles. The large percentage of patients with preliminary prostate-specific antigen values below 1.0 portends efficacy.

Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation

PURPOSE

To compare the dose and volume of bladder and rectum treated using high-dose-rate (HDR) prostate implant boost versus conformal external beam radiotherapy boost, and to use the dose-volume information to perform a critical volume tolerance (CVT) analysis and then estimate the potential for further dose escalation using HDR brachytherapy boost.

METHODS AND MATERIALS

Using CT scan data collected before and after patients underwent HDR prostate implant, a 7-field conformal prostate-only external beam treatment plan and HDR brachytherapy treatment plan were constructed for each patient. Doses to the normal structures were calculated. Dose-volume histograms (DVH) were plotted for comparison of the two techniques. Wilcoxon signed rank test was performed at four dose levels to compare the dose to normal structures between the two treatment techniques. The acute and late effects of HDR brachytherapy were calculated based on the linear-quadratic (LQ) model. CVT analyses were performed to calculate the potential dose gain (PDG) using HDR brachytherapy boost.

RESULTS

The volume of bladder and rectum receiving high dose was significantly less from implant boost. On the average, 0.19 cc of the bladder received 100% of the brachytherapy prescription dose, compared with 5.1 cc of the bladder receiving 100% of the prescription dose in the 7-field conformal external beam radiotherapy boost. Similarly, 0.25 cc of the rectum received 100% of the dose with the implant boost, as compared to 2.9 cc in the conformal external beam treatment. The implant also delivered higher doses inside the prostate volume. On average, 47% of the prostate received > or =150% of the prescription dose. The CVT analysis revealed a range of PDG using the HDR brachytherapy boost which depended on the following variables: critical volume (CV), critical volume tolerance dose (CVTD), number of HDR fractions (N), and the dose of external beam radiotherapy (XRT) delivered with brachytherapy boost. The PDG varied from -3.45% to 10.53% for tumor with an alpha-beta ratio of 10 and 7.14% to 64.6% for tumor with an alpha-beta ratio of 1.5 based on the parameters used for calculation in this study.

CONCLUSIONS

HDR brachytherapy can provide better sparing of rectum and bladder while delivering a higher dose to the prostate. Even with the increased late effects of high dose per fraction, there is still a potential for dose escalation beyond external radiotherapy limits using HDR brachytherapy.

Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy

PURPOSE/OBJECTIVE

Recent studies supported by histopathological correlation suggest that the combined use of endorectal magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) allows differentiation of normal and carcinomatous prostate. The goal of this study was to use static field intensity modulated three-dimensional conformal radiotherapy (SF-IMRT) to treat the entire prostate to a total dose of >70 Gy, while concurrently treating a dominant intraprostatic lesion (DIL) defined by MRI+MRS to 90 Gy while not exceeding normal tissue tolerances.

MATERIALS AND METHODS

For the example chosen, the DIL consisted of a large portion of the peripheral zone of the left lobe of the prostate. University of Michigan (UM-PLAN) three-dimensional treatment planning software was used to design a partially shielded 7 field conformal isodose plan that would treat the entire prostate to >70 Gy at 1.8 Gy per day (80% isodose line), while concurrently treating the DIL to 2.25 Gy per day for a total dose of 90 Gy. Dose volume histograms (DVH) were used to compare the rectal doses to rectum and other adjacent normal tissues using these two techniques.

RESULTS

SF-IMRT as described, allowed a total dose of 90 Gy to encompass the DIL, while the rectal dose was slightly lower than that using the standard 7 field technique to the prostate alone. For example, the dose to 30 cm3 of the rectum was 40 Gy using SF-IMRT and 48 Gy for the standard 7 field technique. Because of differences in the dose per fraction the biologic advantages of the SF-IMRT technique are likely to be even greater.

CONCLUSIONS

This study demonstrates the feasibility of using SF-IMRT to treat a DIL involving a single lobe of the prostate, as defined by MRI/MRS, to 90 Gy, while simultaneously treating the prostate to >70 Gy without increasing the dose to surrounding normal tissues. A similar approach could be used to treat multifocal disease. This method of treatment is an alternative to dynamic intensity modulation. It is less expensive, and can be adapted to any radiation therapy department without the use of an inverse treatment planning programs.

A three-field arc technique (3-FAT) for treating prostate cancer

PURPOSE

We have previously designed two external beam radiotherapy techniques for treating prostate cancer. The seven-field, coplanar fixed beam technique resulted in dose distributions that were superior to other coplanar plans studied. The other technique using bilateral blocked arcs produced slightly higher doses to normal tissues but was far simpler to execute. We combined aspects of both these plans to produce a technique that was less complicated yet resulted in an improved dose distribution, i.e., to improve dose delivery to the clinical target volume (CTV) while minimizing doses to the rectum, bladder, and femoral heads.

METHODS AND MATERIALS

Twenty patients, previously treated at the University of California, San Francisco (UCSF) with radiotherapy for adenocarcinoma of the prostate, were studied. Each patient was treated with an immobilizer, urethrogram, and a preplanning CT scan. A previously employed, seven-field, coplanar, fixed beam technique was compared with a newly designed three-field, arc technique (3-FAT). This 3-FAT was designed using two equally weighted rotational beams, with nonuniform blocks, beginning in the lateral gantry position and spanning anteriorly 35 degrees. The two beams became noncoplanar by turning the table 20 degrees, bringing the patient's feet toward the gantry (inferior oblique arcs). An anterior inferior oblique (AIO), angled 20 degrees to the inferior of anterior was included for 10% of the daily treatment. Dose-volume histograms (DVH) were used to evaluate doses to adjacent critical structures. The dose to each critical structure was averaged and tabulated for the 20 patients. In addition, we compared normalized doses to adjacent structures using 3-FAT and seven-coplanar, fixed beams vs. a technique using four noncoplanar, fixed beams.

RESULTS

The three-field arc technique produced favorable dose distributions for the rectum, bladder, and femoral heads. Compared to the seven-field plan, employing the 3-FAT resulted in a 13% lower dose to 40% of the rectum, and 25% lower dose to 40% of the bladder. Compared to the four-field plan, employing the 3-FAT resulted in a 23% lower dose to 40% of the rectum, and 1% decrease in dose to 40% of the bladder. The three-field arc technique reduced the dose delivered to 40% of the femoral heads by approximately 45% when compared to the other techniques. Compared to other standard treatment techniques, the improvement in dose distribution was even greater.

CONCLUSIONS

The 3-FAT represents a technical improvement in the treatment of cancer of the prostate and seminal vesicles by minimizing the dose delivered to adjacent critical structures. The 3-FAT can incorporate the advances of multileaf collimation and digitally reconstructed radiographs to deliver treatment with cost effectiveness and technological efficiency.

Pulsed low dose rate brachytherapy for pelvic malignancies

PURPOSE

The pulsed low dose rate remote afterloading unit was designed to combine the radiation safety and isodose optimization advantages of high dose rate technology with the radiobiologic advantages of continuous low dose rate brachytherapy. This is the first report of a prospective clinical trial evaluating the relative incidence of acute toxicity and local control in patients with pelvic malignancies who underwent interstitial or intracavitary brachytherapy with the pulsed low dose rate remote afterloader.

METHODS AND MATERIALS

From 5/11/92-6/21/95, 65 patients underwent 77 brachytherapy procedures as part of their treatment regimen for pelvic malignancies. Using the pulsed low dose rate Selectron, equipped with a single cable-driven 0.3-1.0 Ci Ir192 source, target volume doses of 0.40-0.85 Gy per pulse were prescribed to deliver the clinically determined dose. Forty-five intracavitary and 32 interstitial procedures were performed. Fifty-four patients had primary and 11 recurrent disease. Patients were followed closely to assess incidence of Grade 3-5 acute and delayed toxicity, local control, and survival.

RESULTS

With a median follow-up of 16.1 months (range 1-29), 33 patients are NED, 10 alive with disease, 13 dead with disease, 4 dead of intercurrent disease, and 5 lost to follow-up. Local control was maintained until last follow-up or death in 48 cases, local failure occurred in 11, unknown in 5. Grade 3-5 acute toxicities (requiring medical or surgical intervention) occurred in 5 out of 77 procedures (6.5%), delayed complications in 10 patients (15% actuarial incidence at 2 years). In the 52 procedures performed for 42 patients with cervix cancer, the acute toxicity incidence was 5.8%, with a 14% 2-year actuarial incidence of delayed complications. Of 32 interstitial templates performed on 30 patients for pelvic malignancies, there were three incidences of acute toxicity and five delayed toxicities.

CONCLUSION

Using the parameters described for this initial clinical study in patients treated for pelvic malignancies, pulsed low dose rate brachytherapy shows no significant increase in acute toxicity above that seen with the standard continuous low dose rate approach. Using the isodose optimization possible with pulsed brachytherapy, local control is excellent in patients treated at initial presentation, although longer follow-up is required for full assessment of local control and late toxicity. Further trials will need to be carried out to determine if larger doses per pulse and shorter total treatment times have comparable therapeutic ratios.

The use of a partial transmission shield to reduce the optic chiasm doses during radiation therapy treatment of brain tumors

Historically, brain tumors have been treated with lateral opposed beams for 40-45 Gy followed by more conformal reduced fields. Advances in treatment planning computers have led to the implementation of conformal non-axial techniques, allowing for escalation of dose. In patients where total doses exceed 50 Gy, adjacent critical structures can be protected with a partially shielded transmission block over the optic nerves and chiasm. By eliminating the conedown portion of the treatment a more cost and time effective treatment is achieved. Partially shielded blocks can be designed by using cerrobend or multileaf collimation. They can be included in the treatment plan and verified by an irregular field calculation and/ or thermoluminescent dosimeters.

Three dimensional comparison of blocked arcs vs. four and six field conformal treatment of the prostate

PURPOSE

The purpose of this study is to compare five different techniques for treatment the prostate without seminal vesicles. Dose volume histograms and a time survey are the tools that were used for this analysis.

METHODS AND MATERIALS

For this study we compared 3D techniques using four and six field conformal treatments, to open and blocked 8 x 8 cm2 120 degrees bilateral arcs. All the plans were normalized to deliver 100% to the central axis, and full 3D calculations were performed. Blocked arcs were created using the 'average beam's eye view' (A-BEV) technique.

RESULTS

Analysis of the dose volume histograms revealed: (1) Arcs with blocks result in an improved dose distribution compared to standard arcs and four field 3DCRT techniques, (2) The DVH associated with blocked arcs, using block margins of 1.3 cm, resulted in a somewhat lower dose to the rectum but a 'tighter' margin around the prostate compared to the DVH generated using the six field 3DCRT technique.

CONCLUSION

This technique is for treatment of the prostate only, when treatment of the seminal vesicle is not required. The use of blocked arcs significantly improved the dose distribution compared to using standard arcs and 4-field conformal techniques. The DVHs associated with using blocked arcs is comparable to the SFC technique. It is likely to be less expensive, faster to set-up and may allow for safe dose escalation when only the prostate is receiving treatment.

The "critical volume tolerance method" for estimating the limits of dose escalation during three-dimensional conformal radiotherapy for prostate cancer

PURPOSE

To describe the "Critical Volume Tolerance" (CVT) method for defining normal tissue tolerance during 3D-based dose escalation studies for prostate cancer.

METHODS AND MATERIALS

The CVT method predicts the tolerance to radiation for "in series"-type functional units based on the assumption that tolerance depends on a critical threshold "low-volume high-dose region." The data used for describing this model were generated from 3D analysis of randomly selected patients with prostate cancer. Commonly used coplanar four-and six-field conformal (SFC) techniques were chosen as the comparison techniques. For purposes of comparison, rectal tolerance was assumed to be reached following whole pelvic irradiation using a four-field box technique to 50 Gy, followed by a conedown boost to 70 Gy using bilateral 9 x 9 cm 120 degree arcs as popularized by investigators from Stanford University (SUH).

RESULTS

Based on the average dose volume histograms for the patients studied, the maximum safe increase in dose for the SFC technique compared to the SUH technique, would be 10% if 30% of the rectal volume was the critical dose limiting volume (CVT = 30%), 5% if the CVT = 10%, or greater than 20% if the CVT = 40%. Commonly used four-field conformal techniques would not be expected to allow significant escalation of the dose without increasing the risk of complications.

CONCLUSIONS

The CVT method is relatively simple, and data generated based on it can be used to support normal tissue complication probability equations. The CVT method can be verified or modified as partial tolerance data become available. Based on the CVT model, sophisticated treatment techniques should allow a modest increase in the total dose of radiation delivered to the prostate without an increase in late complications.

The impact of isocenter placement errors associated with dose distributions used in irradiating prostate cancer

Historically, four perpendicular treatment fields or bilateral arcs have been used in the treatment of prostate cancer. "New techniques" including four conformal fields, seven conformal fields, 120 degrees bilateral conformal coplanar, and non-coplanar arc'ed beam arrangements, are replacing the "older" approaches. These techniques result in a reduction in doses to adjacent critical structures while covering the clinical target volume (CTV). This study, analyzes the impact of random or systematic isocenter displacement errors (IDE) associated with the delivery of radiotherapy, using the best of these "newer techniques". Dose Volume Histograms (DVH) were used to evaluate the dose to the prostate and surrounding normal tissues with 0.3 cm, 0.5 cm and 0.8 cm IDE. It was determined that IDE associated with fixed coplanar treatment techniques could reduced the prescribed dose to the prostate by 0-8%, the coplanar are technique reduced the prescribed prostate dose by 3-10%, and the noncoplanar conformal arc technique could lower the prescribed prostate dose by 0-5%. Predictably, 0.3 cm IDE found in the posterior and inferior direction increase the dose to the rectum by 5-12% and lowered the dose to the bladder by 4-8%. Errors in the superior and anterior direction increased the dose to the bladder by 4-8% and decreased the dose to the rectum by 8-10%. Errors in the right to left direction slightly increased the dose to the ipsilateral femoral head. Doses to the rectum and bladder associated with 0.5 cm and 0.8 cm IDE are significantly larger. The frequency and magnitude of IDE must be accounted for before higher doses can be delivered safety. Recognizing the impact of IDE on our ability to deliver the prescribed dose to the planning target volumes (PTV) could incorporate the impact of IDE during the planning process.